PMID- 23324122
OWN - NLM
STAT- MEDLINE
DCOM- 20130816
LR  - 20131121
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 40
IP  - 3
DP  - 2013 Mar
TI  - Adverse events following statin-fenofibrate therapy versus statin alone: a 
      meta-analysis of randomized controlled trials.
PG  - 219-26
LID - 10.1111/1440-1681.12053 [doi]
AB  - The combination of fenofibrate with statins is a beneficial therapeutic option 
      for patients with mixed dyslipidaemia, but concerns about adverse events (AEs) 
      make physicians reluctant to use this combination therapy. Medline, Embase and 
      the Cochrane Library were searched to identify 13 randomized controlled trials, 
      involving 7712 patients, of statin-fenofibrate therapy versus statin alone for 
      review. There were significant decreases in low-density lipoprotein-cholesterol, 
      triglycerides and total cholesterol and increases in high-density 
      lipoprotein-cholesterol in patients receiving combination therapy compared with 
      statin therapy alone. The incidence of aminotransferase elevations in the 
      fenofibrate-statin therapy group was significantly higher than in the statin 
      monotherapy group (odds ratio (OR), 1.66; 95% confidence interval (CI) 1.17-2.37; 
      P < 0.05). The incidence of elevated creatine kinase levels (OR 0.88; 95% CI 
      0.63-1.23; P > 0.05), muscle-associated AEs (OR 0.98; 95% CI 0.88-1.09; P > 0.05) 
      and withdrawals attributed to liver and muscle dysfunction did not differ 
      significantly between the two groups. The efficacy of fenofibrate + standard-dose 
      statin and incidence of AEs in the fenofibrate + standard-dose statin group were 
      almost identical to those in the fenofibrate-statin group. In conclusion, 
      combination therapy improves the blood lipid profile of patients. 
      Fenofibrate-statin combination therapy appears to be as well tolerated as statin 
      monotherapy. Physicians should consider fenofibrate-statin combination therapy in 
      patients but monitor aminotransferase levels to avoid hepatic complications.
CI  - (c) 2013 The Authors Clinical and Experimental Pharmacology and Physiology (c) 2013 
      Wiley Publishing Asia Pty Ltd.
FAU - Geng, Qiang
AU  - Geng Q
AD  - Department of Cardiology, Peking University People's Hospital, Beijing, China.
FAU - Ren, Jingyi
AU  - Ren J
FAU - Chen, Hong
AU  - Chen H
FAU - Lee, Chongyou
AU  - Lee C
FAU - Liang, Wenqing
AU  - Liang W
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Lipids)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Dyslipidemias/blood/drug therapy
MH  - Fenofibrate/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Hypolipidemic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Lipids/blood
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2013/01/18 06:00
MHDA- 2013/08/21 06:00
CRDT- 2013/01/18 06:00
PHST- 2012/08/05 00:00 [received]
PHST- 2013/01/07 00:00 [revised]
PHST- 2013/01/10 00:00 [accepted]
PHST- 2013/01/18 06:00 [entrez]
PHST- 2013/01/18 06:00 [pubmed]
PHST- 2013/08/21 06:00 [medline]
AID - 10.1111/1440-1681.12053 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2013 Mar;40(3):219-26. doi: 10.1111/1440-1681.12053.